» Articles » PMID: 34502076

MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Sep 10
PMID 34502076
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The transcription factor CEBPA is a master regulator of liver homeostasis, myeloid cell differentiation and is downregulated in several oncogenic diseases. MTL-CEBPA is a small activating RNA drug which upregulates gene expression of CEBPA for treatment of hepatocellular carcinoma (HCC). We investigate whether MTL-CEBPA has immune modulatory effects by combining MTL-CEBPA with an anti-PD-1 checkpoint inhibitor (CPI) and/or radiofrequency ablation (RFA) in two preclinical models. First, mice with two flanks of HCC tumors (BNL) were treated with combinations of RFA (right flank), anti-PD-1 or MTL-CEBPA. The reduction of the left flank tumors was most pronounced in the group treated with RFA+anti-PD1+MTL-CEBPA and 7/8 animals responded. This was the only group with a significant increase in CD8+ and CD49b+/CD45+ tumor infiltrating lymphocytes (TIL). Second, a combination of anti-PD-1+MTL-CEBPA was tested in a CT26 colon cancer model and this treatment significantly reduced tumor size, modulated the tumor immune microenvironment and increased TILs. These data suggest a clinical role for combination treatment with CPIs, RFA and MTL-CEBPA through synergistic priming of the immune tumor response, enabling RFA and CPIs to have a pronounced anti-tumor effect including activity in non-treated tumors in the case of RFA.

Citing Articles

Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.

Liu M, Wang Y, Zhang Y, Hu D, Tang L, Zhou B Signal Transduct Target Ther. 2025; 10(1):73.

PMID: 40059188 PMC: 11891339. DOI: 10.1038/s41392-024-02112-8.


The colorectal cancer microenvironment: Preclinical progress in identifying targets for cancer therapy.

Meyiah A, Khan F, Alfaki D, Murshed K, Raza A, Elkord E Transl Oncol. 2025; 53:102307.

PMID: 39904281 PMC: 11846588. DOI: 10.1016/j.tranon.2025.102307.


Advancements in clinical RNA therapeutics: Present developments and prospective outlooks.

Saw P, Song E Cell Rep Med. 2024; 5(5):101555.

PMID: 38744276 PMC: 11148805. DOI: 10.1016/j.xcrm.2024.101555.


Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.

Bellone S, Jeong K, Halle M, Krakstad C, McNamara B, Greenman M Proc Natl Acad Sci U S A. 2024; 121(17):e2321898121.

PMID: 38625939 PMC: 11046577. DOI: 10.1073/pnas.2321898121.


Emerging roles of MITF as a crucial regulator of immunity.

Lee A, Lim J, Lim J Exp Mol Med. 2024; 56(2):311-318.

PMID: 38351314 PMC: 10907664. DOI: 10.1038/s12276-024-01175-5.


References
1.
Napoletano C, Taurino F, Biffoni M, De Majo A, Coscarella G, Bellati F . RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. Int J Oncol. 2008; 32(2):481-90. View

2.
Setten R, Lightfoot H, Habib N, Rossi J . Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma. Curr Pharm Biotechnol. 2018; 19(8):611-621. PMC: 6204661. DOI: 10.2174/1389201019666180611093428. View

3.
Nam S, Kang K, Cha J, Kim J, Lee H, Kim Y . Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function. J Leukoc Biol. 2016; 100(6):1273-1284. DOI: 10.1189/jlb.1A0215-068RR. View

4.
Torroella-Kouri M, Ma X, Perry G, Ivanova M, Cejas P, Owen J . Diminished expression of transcription factors nuclear factor kappaB and CCAAT/enhancer binding protein underlies a novel tumor evasion mechanism affecting macrophages of mammary tumor-bearing mice. Cancer Res. 2005; 65(22):10578-84. PMC: 2963077. DOI: 10.1158/0008-5472.CAN-05-0365. View

5.
den Brok M, Sutmuller R, Nierkens S, Bennink E, Frielink C, Toonen L . Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer. 2006; 95(7):896-905. PMC: 2360548. DOI: 10.1038/sj.bjc.6603341. View